恶性淋巴细胞产生的纯化纤溶酶原激活因子可消除淋巴细胞的细胞毒性。
Purified plasminogen activating factor produced by malignant lymphoid cells abrogates lymphocyte cytotoxicity.
作者信息
Sundar S K, Bergeron J, Menezes J
出版信息
Clin Exp Immunol. 1984 Jun;56(3):701-8.
Immunosuppression is a generally observed phenomenon in patients with malignancies. Here we report that plasminogen activating factor (PAF) produced by human (P3HR-1) and simian (B95-8) lymphoid cells of malignant origin abrogates lymphocyte cytotoxicity. PAF has been purified from Epstein-Barr (EB) virus genome carrying lymphocyte cytotoxicity. PAF has been purified from Epstein-Barr (EB) virus genome carrying lymphoid lines by affinity chromatography using lysine-Sepharose columns. Purified PAF consistently inhibited Killer cell activity against the following targets: K-562, EB virus superinfected Raji cells and in vitro EB virus transformed autologous B lymphocytes. Furthermore PAF also inhibited the antibody-dependent cellular cytotoxicity. The results presented also indicate that PAF affects the effector lymphocytes and not the target cells. Taken together, these observations emphasize the importance of factors such as PAF, released by malignant cells, as inhibitors/modulators of immune mechanisms effective against tumour cells.
免疫抑制是恶性肿瘤患者中普遍观察到的一种现象。在此我们报告，源自人类（P3HR-1）和猿猴（B95-8）的恶性淋巴样细胞产生的纤溶酶原激活因子（PAF）可消除淋巴细胞的细胞毒性。PAF已从携带淋巴细胞细胞毒性的爱泼斯坦-巴尔（EB）病毒基因组中纯化出来。通过使用赖氨酸-琼脂糖柱的亲和层析法，已从携带淋巴样细胞系的EB病毒基因组中纯化出PAF。纯化的PAF持续抑制杀伤细胞对以下靶标的活性：K-562、EB病毒超感染的拉吉细胞以及体外EB病毒转化的自体B淋巴细胞。此外，PAF还抑制抗体依赖性细胞毒性。所呈现的结果还表明，PAF影响效应淋巴细胞而非靶细胞。综上所述，这些观察结果强调了诸如PAF等由恶性细胞释放的因子作为对肿瘤细胞有效的免疫机制的抑制剂/调节剂的重要性。
Zotero 插件